Cargando…
PB2077: POD12 AND POD24 – A NEW SURROGATE MARKER IN MANTLE CELL LYMPHOMA TREATMENT?
Autores principales: | Freitas, J., Pereira, D., Moreira, C., Chacim, S., Domingues, N., Espírito Santo, A., Martins, Â., Oliveira, I., Viterbo, L., Moreira, I., Mariz, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431633/ http://dx.doi.org/10.1097/01.HS9.0000851140.58553.2a |
Ejemplares similares
-
PB2576: NEWS, NEWS2 AND QSOFA ACCURACY TO PREDICT SEPSIS-RELATED MORTALITY IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE-CENTRE ANALYSIS
por: Meireles, Ana Maria, et al.
Publicado: (2023) -
Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience
por: Couto, Maria Eduarda, et al.
Publicado: (2021) -
PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022) -
PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022) -
PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
por: Valentin Hansen, Simone, et al.
Publicado: (2023)